Our Research

MDMA-Assisted Psychotherapy Research

MDMA for PTSD

Status – Enrolling
After preliminary studies demonstrated safety and efficacy in the treatment of PTSD, a serious and life-threatening condition, the FDA granted Breakthrough Therapy designation for MDMA-assisted psychotherapy.

 

MDMA for Social Anxiety in Autistic Adults

Status – Enrollment Complete
Based on the known effects of MDMA, and individual reports, this study explored the use of MDMA-assisted psychotherapy for enhancing social skills and quality of life in autistic adults with social anxiety.

 

MDMA for Anxiety Related to Life-Threatening Illnesses

Status – Enrollment Complete
Facing a life-threatening illness can cause psychological symptoms that are often not addressed during treatment of the physical condition. We studied whether MDMA-assisted psychotherapy could help adults cope with the anxiety related to life-threatening illnesses.

Investigator-Initiated Trials

What is PTSD?

Cannabis Research

Cannabis for PTSD

Status – Enrollment Complete
MAPS received regulatory approval to conduct a study of smoked cannabis for symptoms of PTSD in veterans of war. The trial investigated four different potencies of cannabis to see what is most safe and effective for reducing PTSD symptoms.

 

View All MAPS PBC Studies

Help Us Get More Treatments to Phase 3 and Potentially Beyond

MAPS Public Benefit Corporation

Our Mission
Who We Are
Careers
News
FAQ
Contact Us
Privacy Policy

3141 Stevens Creek Blvd #40547
San Jose, CA 95117

✕

MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS). MAPS is a 501(c)(3) non-profit research and educational organization.

Stay Up-to-Date about the MDMA-AT Education Program

You have Successfully Subscribed!